Literature DB >> 8216689

Combined cyclosporin A-steroid-MTX treatment in endogenous non-infectious uveitis.

L Pascalis1, G Pia, G Aresu, T Frongia, L Barca.   

Abstract

Thirty-two patients with endogenous uveitis resistant to treatment with high doses of cortisone and other immunosuppressive agents were treated with cyclosporin A (at an initial dose of 5 mg/kg/die, subsequently modified according to individual clinical response), fluocortolone and methotrexate. Total and lasting disease remission was obtained in all patients, together with the recovery of normal visual acuity in 20 cases and its significant improvement in the remaining 12. Furthermore, in all patients the total disappearance of all ocular inflammatory activity was observed and maintained for a period of 10.87 +/- 5.31 (6-18) months. No signs of renal or hepatic toxicity were observed in any of the patients. A form of hirsutism appeared in only two cases.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8216689     DOI: 10.1006/jaut.1993.1039

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  5 in total

Review 1.  Immunosuppressive therapy for chronic uveitis: optimising therapy with steroids and cyclosporin A.

Authors:  A D Dick; M Azim; J V Forrester
Journal:  Br J Ophthalmol       Date:  1997-12       Impact factor: 4.638

Review 2.  Chronic non-infectious uveitis in the elderly: epidemiology, pathophysiology and management.

Authors:  Rajen Gupta; Philip I Murray
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

Review 3.  Peripheral Ulcerative Keratitis: A Review.

Authors:  Kiana Hassanpour; Reem H ElSheikh; Amir Arabi; Charles R Frank; Abdelrahman M Elhusseiny; Taher K Eleiwa; Shiva Arami; Ali R Djalilian; Ahmad Kheirkhah
Journal:  J Ophthalmic Vis Res       Date:  2022-04-29

4.  Integrated Analysis of Key Pathways and Drug Targets Associated With Vogt-Koyanagi-Harada Disease.

Authors:  Zhijun Chen; Zhenyu Zhong; Wanyun Zhang; Guannan Su; Peizeng Yang
Journal:  Front Immunol       Date:  2020-12-15       Impact factor: 7.561

5.  Efficacy, safety and cost-effectiveness of methotrexate, adalimumab or their combination in non-infectious non-anterior uveitis: a protocol for a multicentre, randomised, parallel three arms, active-controlled, phase III open label with blinded outcome assessment study.

Authors:  Ana Belen Rivas; Amanda Lopez-Picado; Valentina Calamia; Ester Carreño; Lidia Cocho; Miguel Cordero-Coma; Alex Fonollosa; Felix M Francisco Hernandez; Angel Garcia-Aparicio; Javier Garcia-Gonzalez; Jose Juan Mondejar; Leticia Lojo-Oliveira; Llucí Martínez-Costa; Santiago Munoz; Diana Peiteado; Jose Antonio Pinto; Beatriz Rodriguez-Lozano; Esperanza Pato; David Diaz-Valle; Elena Molina; Luis Alberto Tebar; Luis Rodriguez-Rodriguez
Journal:  BMJ Open       Date:  2022-03-22       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.